November 25th 2023
From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.
November 20th 2023
Clinical Consultations™: Integrating Modern Antipsychotic Medications into the Management of Patients with Schizophrenia
View More
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Visualizing the Role of Antipsychotics in the Management of Schizophrenia: What is the Role of TAAR1?
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
5th Annual International Congress on the Future of Neurology®
View More
DBS Curbs Major Depression and OCD
July 17th 2006Deep brain stimulation (DBS) may hold promise for patients with treatment-resistant and severe major depression and obsessive-compulsive disorder (OCD). However, it may not be the best choice for patients with Parkinson (PD) disease who display certain compulsive behaviors, reported researchers from the Cleveland Clinic and from Brown Medical School (Providence, Rhode Island) at the annual meeting of the American Academy of Neurological Surgeons, which took place April 22-27 in San Francisco.
Read More
Brain Stimulation Methods for Treating Depression
February 3rd 2006Well into the 1970s, we psychiatrists believed that depression came from anger turned inward-and we acted on this notion. Psychiatrists spent countless hours trying to get depressed patients to talk about their anger. Enterprising psychologists and psychiatrists devised schemes to make such patients angry.
Read More
STAR*D Preliminary Findings Provide Clearer Picture of Major Depressive Disorder
February 1st 2006Funded by the National Institute of Mental Health, the STAR*D project is one of the largest depression treatment studies ever conducted, with more than 4,000 participants. Results from the second phase of the study will be published over the next year. In this issue PT readers will find a preliminary review of data drawn from the first 1,500 enrollees.
Read More
Postpartum Anxiety or Depression? Diagnosis and Treatment in Nursing Mothers
November 1st 2005Women with postpartum depression frequently experience intrusive, obsessive ruminations that are part of a depressive episode. Many women with postpartum depression have significant anxiety, and many reach the level of meeting criteria for full-blown anxiety disorders. An anxiety disorder may also precede and contribute to the development of a depressive episode.
Read More
Testosterone Deficiency, Depression and Sexual Function in Aging Men
October 1st 2005There is growing epidemiologic and clinical data that confirm progressive hypothalamic-pituitary-gonadal hypofunctioning in aging men. What role does the HPG axis play in the complex psychobiology of male sexual and affective disorders? The treatment rationale, clinical indications and risks in using exogenous testosterone for late-life depression are explored.
Read More
Depression, Stress and the Risk of Heart Disease
October 1st 2005In recent years, depression and stress have emerged in the discussion of the impact of psychosocial aspects on coronary heart disease. Several studies indicate that these factors result in risk elevation comparable to hypercholesterolemia and hypertension.
Read More
Impact of ECT on Health-Related Quality of Life and Function in Patients With Depression
October 1st 2005Health-related quality of life can provide a simultaneous and net assessment of the therapeutic and adverse affects of psychiatric treatments for depression. While the cognitive side effects of ECT might be thought of as a limiting factor in HRQOL gains, they have not been systematically studied until recently. Find out what quantitative assessment of HRQOL following ECT for major depressive disorder shows.
Read More
Understanding the Role of Sigma-1 Receptors in Psychotic Depression
October 1st 2005Selective serotonin reuptake inhibitors have been shown effective in the treatment of depression with psychosis. This efficacy appears to correlate with the SSRIs’ level of affinity at the sigma-1 receptors in the brain. What role does the sigma-1 receptor play in psychotic depression? Based on this role, are there implications for other treatments?
Read More
Where Research Paths Converge: Improving Treatments for Depression
October 1st 2005By 2020, depression will be the second leading cause of death and disability worldwide. As the importance of depression as a public health problem has been reinforced, research efforts have followed different paths. Read about some of the latest developments.
Read More
Family Therapy in the Treatment of Depression
October 1st 2005When a family member is diagnosed with depression the whole family is affected. Additional family and marital stresses imposed on the patient with depression can add to the severity of depression and affect long-term remission rates. In order to ensure the best possible success in treatment, the therapist should integrate the family into the patient’s treatment.
Read More
Updates Show Progress in TMS for Depression and Schizophrenia
September 1st 2005Updates Show Progress in TMS for Depression and Schizophrenia by Arline Kaplan In research presented at the 2005 APA annual meeting, transcranial magnetic stimulation is showing efficacy in treating depression and schizophrenia in the research setting. The question of how to translate those findings to a real-world setting still remains.
Read More
Shedding Light on the 'Black Box': Treating Pediatric Depression
May 1st 2005The FDA has issued a "black box" warning about the use of all antidepressants in the pediatric population due to a 1.8-fold increase in suicidality on drug compared to placebo. Yet these medications can be an effective tool in treating depression. How should parents and patients be educated, considering this information?
Read More
Sweet Sorrow: The Relationship Between Depression and Diabetes Mellitus
April 1st 2005Multiple studies show that diabetes approximately doubles the risk of comorbid depression. Furthermore, major depressive disorder is a risk factor for the subsequent development of type 2 diabetes mellitus. Treatments for depression in the setting of diabetes must be evaluated for their effects on blood glucose levels, propensity for weight gain, possible concomitant use for diabetic neuropathy and potential drug interactions.
Read More
Depression as Co-Pilot: Clinical Implications of Hepatitis C and Interferon/Ribavirin Treatment
April 1st 2005Comorbid substance use disorders may complicate treatment for both the hepatologist and psychiatrist. Comprehensive assessment of psychiatric illness and psychopharmacological management may be critical.
Read More
Genomic Keys to Depression Could Unlock Antidepressant Response
March 1st 2005Three recently published studies uncovered some answers to the genetic underpinnings of depression. Familial vulnerability was shown to increase with each generation affected by depression. Two genetic variants pointed in opposite directions: one showed an increase risk of depression and the other predicted responsiveness to antidepressants.
Read More
Neuropsychiatric Symptoms in Poststroke Patients
January 1st 2005The prevalence of major depression following stroke ranges from 10% to 40%. Other psychiatric disorders, including anxiety disorders, apathy and cognitive impairment are also common. Psychiatrists need to be on the lookout for symptoms not just immediately poststroke, but up to six months after the event.
Read More